141 related articles for article (PubMed ID: 18690032)
1. Mutational analysis of block and facilitation of HERG current by a class III anti-arrhythmic agent, nifekalant.
Hosaka Y; Iwata M; Kamiya N; Yamada M; Kinoshita K; Fukunishi Y; Tsujimae K; Hibino H; Aizawa Y; Inanobe A; Nakamura H; Kurachi Y
Channels (Austin); 2007; 1(3):198-208. PubMed ID: 18690032
[TBL] [Abstract][Full Text] [Related]
2. Structural requirements of human ether-a-go-go-related gene channels for block by bupivacaine.
Siebrands CC; Friederich P
Anesthesiology; 2007 Mar; 106(3):523-31. PubMed ID: 17325511
[TBL] [Abstract][Full Text] [Related]
3. Molecular determinants of hERG channel block by terfenadine and cisapride.
Kamiya K; Niwa R; Morishima M; Honjo H; Sanguinetti MC
J Pharmacol Sci; 2008 Nov; 108(3):301-7. PubMed ID: 18987434
[TBL] [Abstract][Full Text] [Related]
4. Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.
Du C; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2014 Sep; 74(100):220-30. PubMed ID: 24877995
[TBL] [Abstract][Full Text] [Related]
5. The molecular determinants of R-roscovitine block of hERG channels.
Cernuda B; Fernandes CT; Allam SM; Orzillo M; Suppa G; Chia Chang Z; Athanasopoulos D; Buraei Z
PLoS One; 2019; 14(9):e0217733. PubMed ID: 31479461
[TBL] [Abstract][Full Text] [Related]
6. Molecular determinants of hERG potassium channel inhibition by disopyramide.
El Harchi A; Zhang YH; Hussein L; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2012 Jan; 52(1):185-95. PubMed ID: 21989164
[TBL] [Abstract][Full Text] [Related]
7. A mechanism underlying compound-induced voltage shift in the current activation of hERG by antiarrhythmic agents.
Furutani K; Yamakawa Y; Inanobe A; Iwata M; Ohno Y; Kurachi Y
Biochem Biophys Res Commun; 2011 Nov; 415(1):141-6. PubMed ID: 22020101
[TBL] [Abstract][Full Text] [Related]
8. Facilitation of
Furutani K; Tsumoto K; Chen IS; Handa K; Yamakawa Y; Sack JT; Kurachi Y
J Gen Physiol; 2019 Feb; 151(2):214-230. PubMed ID: 30674563
[TBL] [Abstract][Full Text] [Related]
9. Structural determinants of HERG channel block by clofilium and ibutilide.
Perry M; de Groot MJ; Helliwell R; Leishman D; Tristani-Firouzi M; Sanguinetti MC; Mitcheson J
Mol Pharmacol; 2004 Aug; 66(2):240-9. PubMed ID: 15266014
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: mode of action.
Kushida S; Ogura T; Komuro I; Nakaya H
Eur J Pharmacol; 2002 Dec; 457(1):19-27. PubMed ID: 12460639
[TBL] [Abstract][Full Text] [Related]
11. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
12. High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656.
Ridley JM; Milnes JT; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2004 Dec; 325(3):883-91. PubMed ID: 15541373
[TBL] [Abstract][Full Text] [Related]
13. Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.
Zhang Y; Colenso CK; El Harchi A; Cheng H; Witchel HJ; Dempsey CE; Hancox JC
Biochem Pharmacol; 2016 Aug; 113():24-35. PubMed ID: 27256139
[TBL] [Abstract][Full Text] [Related]
14. Papaverine, a vasodilator, blocks the pore of the HERG channel at submicromolar concentration.
Kim YJ; Hong HK; Lee HS; Moh SH; Park JC; Jo SH; Choe H
J Cardiovasc Pharmacol; 2008 Dec; 52(6):485-93. PubMed ID: 19034039
[TBL] [Abstract][Full Text] [Related]
15. Structural implications of hERG K
Helliwell MV; Zhang Y; El Harchi A; Du C; Hancox JC; Dempsey CE
J Biol Chem; 2018 May; 293(18):7040-7057. PubMed ID: 29545312
[TBL] [Abstract][Full Text] [Related]
16. Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine.
Sánchez-Chapula JA; Navarro-Polanco RA; Sanguinetti MC
Naunyn Schmiedebergs Arch Pharmacol; 2004 Dec; 370(6):484-91. PubMed ID: 15558243
[TBL] [Abstract][Full Text] [Related]
17. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
[TBL] [Abstract][Full Text] [Related]
18. Molecular determinants of HERG channel block.
Kamiya K; Niwa R; Mitcheson JS; Sanguinetti MC
Mol Pharmacol; 2006 May; 69(5):1709-16. PubMed ID: 16474003
[TBL] [Abstract][Full Text] [Related]
19. The evolutionarily conserved residue A653 plays a key role in HERG channel closing.
Stepanovic SZ; Potet F; Petersen CI; Smith JA; Meiler J; Balser JR; Kupershmidt S
J Physiol; 2009 Jun; 587(Pt 11):2555-66. PubMed ID: 19406877
[TBL] [Abstract][Full Text] [Related]
20. Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action.
Kiesecker C; Zitron E; Lück S; Bloehs R; Scholz EP; Kathöfer S; Thomas D; Kreye VA; Katus HA; Schoels W; Karle CA; Kiehn J
Naunyn Schmiedebergs Arch Pharmacol; 2004 Dec; 370(6):423-35. PubMed ID: 15599706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
